Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Pagaya Expands PAID Shelf with Prosper: Closing $115 Million Consumer Credit ABS
-
First Mining Establishes At-The-Market Facility
-
Cantor Fitzgerald Reiterates Overweight Rating on PolarityTE (PTE)
-
AnaptysBio (ANAB) CFO Resignation Is Not A Read Into Trials - Cantor
-
Lineage Cell Therapeutics to Ring Opening Bell at the New York Stock Exchange on August 21, 2019
-
Sarepta Therapeutics (SRPT) PT Lowered to $175 at Cantor Fitzgerald
-
Oil steadies as hopes of easing trade tensions lend support
-
Foamix (FOMX) Enters Sale Agreement with Cantor Fitzgerald Covering up to $30M in Stock
-
Cantor Fitzgerald Starts Immunomedics (IMMU) at Overweight
-
U.S. SEC fines Cantor, BMO Capital Markets over improper handling of ADRs
-
U.S. 30-year yields drop to record low; 10-year yields sink
-
Pre-Open Movers 08/15: (PVTL) (JCP) (WMT) Higher; (BGG) (TPR) (CSCO) (more...)
-
Mallinckrodt plc (MNK) Positive CONFIRM Results Confirm Hidden Value, Cantor Fitzgerald Reiterates Overweight
-
TherapeuticsMD (TXMD) Should Benefit From NuvaRing Delay - Cantor Fitzgerald
-
UPDATE: Cantor Fitzgerald Starts Geron Corporation (GERN) at Overweight
-
Amarin Corporation (AMRN) Reiterated Overweight At Cantor Fitzgerald
-
Orchid Island Capital Announces August 2019 Monthly Dividend and July 31, 2019 RMBS Portfolio Characteristics
-
Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update
-
Northern Dynasty Announces Closing of US$11.5 Million Bought Deal
-
Thunder Bridge Acquisition II, Ltd. Announces Closing of $345,000,000 Initial Public Offering
-
Thunder Bridge Acquisition II, Ltd. Announces Closing of $345,000,000 Initial Public Offering
-
Health Insurance Innovations (HIIQ) Negative Cash Flow Is Not A Concern - Cantor Fitzgerald
-
AAC Holdings, Inc. Reports Preliminary Estimated Operational Highlights for Second Quarter 2019
-
Cantor Fitzgerald Downgrades Abeona Therapeutics (ABEO) to Neutral
-
Cantor Fitzgerald Upgrades Humana (HUM) to Overweight
-
Northern Dynasty Increases Previously Announced Bought Deal to US$10 Million
-
Amarin Corporation (AMRN) - Negative Reaction To AdCom Is Overdone - Cantor
-
Aclaris Therapeutis (ACRS) PT Lowered to $5 at Cantor Fitzgerald
-
Thunder Bridge Acquisition II Ltd. (THBR) Prices 30M Unit IPO at $10/Unit
-
Stemline Therapeutics (STML) Prices 5M Share Common Offering at $15.25/Sh
-
Ascendant Resources Inc. (ASND:CN) (ASDRF) PT Lowered to Cdn$1 at Cantor Fitzgerald
-
Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock
-
Northern Dynasty announces US$8.0 million bought deal and concurrent up to US$2.0 million private placement
-
Thunder Bridge Acquisition II, Ltd. Announces Pricing of $300,000,000 Initial Public Offering
-
Thunder Bridge Acquisition II, Ltd. Announces Pricing of $300,000,000 Initial Public Offering
-
Catalyst Pharmaceutical Partners (CPRX) PT Raised to $12 at Cantor Fitzgerald
-
Royal Gold (RGLD) PT Raised to $125 at Cantor Fitzgerald
-
PolarityTE (PTE) PT Lowered to $50 at Cantor Fitzgerald; 'Early Signs of Implementation of Initiatives'
-
G.research LLC Announces Management Changes
-
Great Panther Closes US$17.25 Million Bought Deal Financing
-
Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
-
Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
-
Cara Therapeutics Reports Second Quarter 2019 Financial Results
-
Cara Therapeutics Reports Second Quarter 2019 Financial Results
-
Correvio Closes Public Offering of 9,200,000 Common Shares
-
Evolent Health (EVH) PT Lowered to $16 at Cantor Fitzgerald
-
Computer Programs and Systems (CPSI) PT Lowered to $26 at Cantor Fitzgerald
-
Benefitfocus (BNFT) PT Lowered to $47 at Cantor Fitzgerald
-
AxoGen, Inc. (AXGN) PT Lowered to $21 at Cantor Fitzgerald
-
Allergen (AGN) PT Raised to $165 at Cantor Fitzgerald

